Published in Cancer Weekly, January 11th, 2005
The notes bear interest at 8% per annum and are freely convertible into shares of the company's common stock at a price of $0.40 per share. The conversion price represents the 10-day volume weighted average trading price of the company's common stock. As part of this transaction, Neoprobe issued 5-year warrants to the investors to purchase 10,125,000 shares of the company's common stock at an exercise price of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.